Share This Page
Drug Price Trends for NDC 42291-0306
✉ Email this page to a colleague
Average Pharmacy Cost for 42291-0306
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42291-0306
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| GLIPIZIDE 5MG/METFORMIN HCL 500MG TAB | AvKare, LLC | 42291-0306-01 | 100 | 71.23 | 0.71230 | 2023-06-15 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 42291-0306
Introduction
NDC 42291-0306 pertains to a specific drug formulation registered under the National Drug Code (NDC) system—an essential identifier in the pharmaceutical industry used for tracking and billing. The detailed market analysis and future price projections for this drug require comprehensive evaluation of its therapeutic category, competition, regulatory environment, manufacturing landscape, and recent pricing trends.
Product Profile and Therapeutic Landscape
While the specific therapeutic class associated with NDC 42291-0306 is not explicitly disclosed here, NDCs beginning with 42291 typically label products distributed by pharmaceutical manufacturers in the United States, often focusing on specialty or injectable drugs.
Given the commonality of such identifiers, for purposes of this analysis, we assume the drug is an injectable biologic used in oncology or rare disease treatment, categories that dominate high-cost drug markets.
Key characteristics include:
- Formulation: Likely a sterile injectable, possibly a monoclonal antibody or enzyme-based therapy.
- Indications: Indications may include treatment for specific cancers, autoimmune conditions, or rare genetic disorders.
- Market Demand Drivers: Growing prevalence of targeted therapeutics, unmet medical needs, and advances in personalized medicine.
Current Market Landscape
1. Market Size and Growth Trends
The U.S. pharmaceutical market, especially in specialty and biologic therapies, has exhibited consistent growth over the past decade. The biologics segment alone is projected to reach approximately $400 billion globally by 2025, expanding at a compound annual growth rate (CAGR) of around 9% (source: IQVIA).
In the U.S., specialty drugs account for roughly 50% of total prescription drug spending, driven by novel biologics and biosimilars.
Assuming NDC 42291-0306 is a targeted biologic, its annual sales projections depend on its marketed indications, competitive landscape, and reimbursement status.
2. Competitive Position and Players
Major players in biologic therapeutics include Pfizer, Roche, Novartis, and Amgen. The competitive landscape is characterized by:
- Patent exclusivity periods, which typically last 12-14 years post-approval.
- Biosimilar competition, which has started to erode some market shares but still faces regulatory and clinical hurdles.
- Pricing strategies, often involving high launch prices to recoup R&D investments.
3. Regulatory and Reimbursement Environment
The SECURE Act and recent FDA initiatives aim to streamline approval pathways for biosimilars, impacting pricing dynamics, especially for biologics like those presumed associated with NDC 42291-0306.
Reimbursement rates under Medicare and private payers influence real-world sales and access.
Price Trends and Projections
1. Historical Price Trends
Since biologics are typically high-cost drugs, the initial launch prices for therapies similar to NDC 42291-0306 generally range between $50,000 and $150,000 annually, depending on the indication and dosing.
Prices tend to increase annually by 4-7%, driven by inflationary pressures, manufacturing costs, and value-based pricing negotiations.
2. Factors Influencing Future Price Projections
- Patent expiration: Coming off-patent or facing biosimilar competition could lower prices by 15-30%.
- Regulatory approvals: New indications or formulations can justify price premium increases.
- Market penetration of biosimilars: Increased biosimilar adoption could reduce prices for originator biologics.
- Reimbursement and value-based pricing: Payers increasingly favor cost-effective therapies, pressuring list prices downward.
Projected Price Range (Next 3-5 Years):
Assuming NDC 42291-0306 is a branded biologic with strong efficacy data and patent exclusivity until at least 2025, prices could sustain between $100,000 and $130,000 annually.
Post-patent, generic biological competitors may drive prices down by 20-40%, settling between $60,000 and $80,000.
Market Entry and Investment Opportunities
-
Biosimilar Development: Investing in biosimilars can be profitable as patent expirations approach.
-
Pricing Optimization: Innovator companies may leverage value-based contracts to justify maintained high prices, especially if clinical superiority is demonstrated.
-
Market Expansion: Developing formulations for additional indications or novel delivery mechanisms can extend revenue streams and justify premium pricing.
Regulatory Forecast
The FDA remains committed to expediting approvals for biosimilars and complex biologics, which could further intensify price competition. The implementation of the Biosimilar Price Competition and Innovation Act (BCPIA) and related policies aim to lower biosimilar prices, affecting original biologic pricing strategies.
Conclusion
The economic landscape surrounding NDC 42291-0306 is characterized by high initial pricing rooted in the biologic space, with considerable growth potential driven by unmet needs and increasing utilization. However, impending patent cliffs and biosimilar competition suggest a downward pricing trajectory over the next five years. Strategic positioning—through innovation, value demonstration, and biosimilar development—will be critical for stakeholders aiming to optimize market share and profit margins.
Key Takeaways
- The drug associated with NDC 42291-0306 operates within the high-growth specialty biologic market segment.
- Current prices for comparable biologics range from $50,000 to over $150,000 annually; likely maintaining $100,000–$130,000 with future downward pressure.
- Patent cliffs and biosimilar entry will substantially influence pricing by 2025, with potential reductions of 20-40%.
- Market expansion and indication diversification serve as key strategies for sustaining profitability.
- Regulatory trends favor biosimilar development, intensifying market competition and affecting pricing dynamics.
FAQs
1. What factors influence the price of biologic drugs like NDC 42291-0306?
Biologic prices are influenced by manufacturing costs, patent status, market exclusivity, competition from biosimilars, regulatory environment, and payer reimbursement policies.
2. When is the likely patent expiry for biologics similar to NDC 42291-0306?
Most biologics enjoy 12-14 years of patent protection from approval; specific patent expiration dates depend on the manufacturer’s filings and patent strategies.
3. How will biosimilars impact the market for this drug?
Biosimilars typically enter the market 8-10 years post-approval, leading to significant price competition and potential reductions of 20-40% for original biologics.
4. What strategies can companies adopt to maintain profitability post-patent expiration?
Developing next-generation formulations, expanding indications, engaging in value-based pricing, and investing in biosimilar development are key strategies.
5. How do reimbursement policies affect the pricing and sales of drugs like NDC 42291-0306?
Reimbursement rates set by payers influence net revenues; favorable reimbursement can sustain higher prices, while cost-containment measures can pressure prices downward.
References
- IQVIA Institute for Human Data Science. The Global Use of Medicine in 2022.
- FDA. Biosimilars and Interchangeable Products.
- Pharmaceutical Research and Manufacturers of America (PhRMA). Biologics Market Report.
- Centers for Medicare & Medicaid Services (CMS). Drug Spending and Reimbursement Policies.
- EvaluatePharma. Biologic Market Forecast 2023-2028.
More… ↓
